Nagabuchi E, VanderKolk W E, Une Y, Ziegler M M
Division of Pediatric Surgery, Children's Hospital Research Foundation, Children's Hospital Medical Center, Cincinnati, OH 45299, USA.
J Pediatr Surg. 1997 Feb;32(2):287-93. doi: 10.1016/s0022-3468(97)90196-2.
The finding that angiogenesis plays an important role in the progression and metastasis of malignant tumors has led to the development of several antiangiogenic drugs. The authors report here an examination of the effect of the antiangiogenic agent TNP-470 on the growth, metastases, and survival of two differing murine neuroblastoma cell lines, TBJ and C1300. We found that TNP-470 significantly reduced primary tumor volumes in mice injected with either cell line. In addition, antiangiogenic therapy significantly reduced the size of axillary lymph node metastases in both groups as well as decreased the size of liver metastases in mice receiving TBJ neuroblastoma. TNP-470 treatment also improved animal survival. These data suggest that antiangiogenic therapy retards the growth of primary and metastatic murine neuroblastoma. We speculate that antiangiogenic therapy may be a useful therapeutic modality in the treatment of advanced neuroblastoma once side effects and appropriate dosage requirements are determined.
血管生成在恶性肿瘤的进展和转移中起重要作用这一发现，已促使多种抗血管生成药物得以研发。作者在此报告了抗血管生成剂TNP - 470对两种不同的小鼠神经母细胞瘤细胞系TBJ和C1300的生长、转移及存活影响的研究。我们发现，TNP - 470显著减小了注射任一细胞系的小鼠的原发性肿瘤体积。此外，抗血管生成疗法显著减小了两组小鼠腋窝淋巴结转移灶的大小，并且减小了接受TBJ神经母细胞瘤的小鼠肝脏转移灶的大小。TNP - 470治疗还提高了动物存活率。这些数据表明，抗血管生成疗法可延缓原发性和转移性小鼠神经母细胞瘤的生长。我们推测，一旦确定了副作用和合适的剂量要求，抗血管生成疗法可能会成为治疗晚期神经母细胞瘤的一种有用的治疗方式。
